# MULTI-SERVICE MEDISPA - INVESTMENT COMMITTEE PRESENTATION

**Private Equity Investment Summary | 2-Slide Executive Overview**

---

## SLIDE 1: INVESTMENT HIGHLIGHTS

### üéØ **INVESTMENT THESIS: RESILIENT HEALTHCARE SERVICES PLATFORM**

**Enterprise Value:** $5.97M | **Equity Value:** $3.82M | **EV/EBITDA:** 5.5x

---

### üìä **FINANCIAL PERFORMANCE TRENDS**

| **Key Metrics**       | **2022** | **2023** | **2024** | **CAGR**         |
| --------------------- | -------- | -------- | -------- | ---------------- |
| **Total Revenue**     | $3.57M   | $3.62M   | $3.73M   | **+2.2%**        |
| **Gross Profit**      | $2.49M   | $2.55M   | $2.62M   | **+2.7%**        |
| **Operating Income**  | $650K    | $1.13M   | $1.43K   | **+48.3%**       |
| **Gross Margin**      | 69.8%    | 70.4%    | 70.4%    | **Stable**       |
| **Normalized EBITDA** | $817K    | $1.28M   | $1.08M\* | **29.1% Margin** |

\*Adjusted for marketing normalization ($484K impact)

---

### üèóÔ∏è **SERVICE LINE DIVERSIFICATION STORY**

**Portfolio Composition (2024 Revenue Mix):**

| **Growth Engines (65.5%)** | **Revenue**   | **Trend** | **Margin** |
| -------------------------- | ------------- | --------- | ---------- |
| **Surgery**                | $733K (19.7%) | +9.0% ‚ÜóÔ∏è  | 81.4%      |
| **Wellness**               | $764K (20.5%) | +16.0% ‚ÜóÔ∏è | 64.8%      |
| **Weight Loss**            | $718K (19.3%) | +7.9% ‚ÜóÔ∏è  | 62.8%      |

| **Mature/Declining (31.6%)** | **Revenue**   | **Trend** | **Margin** |
| ---------------------------- | ------------- | --------- | ---------- |
| **Injectables**              | $930K (25.0%) | -9.0% ‚ÜòÔ∏è  | 70.1%      |
| **Energy Devices**           | $246K (6.6%)  | -12.0% ‚ÜòÔ∏è | 90.2%      |

| **Stable Revenue (9.0%)** | **Revenue**  | **Trend** | **Margin** |
| ------------------------- | ------------ | --------- | ---------- |
| **Retail Sales**          | $335K (9.0%) | +1.8% ‚Üí   | 61.2%      |

---

### üí™ **KEY VALUE DRIVERS**

**‚úÖ COMPETITIVE ADVANTAGES:**

- **Sticky Customer Base:** Healthcare services with recurring treatment cycles
- **Pricing Power:** 70%+ gross margins demonstrate strong value proposition
- **Operational Leverage:** 48% operating income CAGR vs 2% revenue growth
- **Diversified Revenue:** 6 service lines reduce single-point-of-failure risk

**‚úÖ QUALITY CHARACTERISTICS:**

- **Predictable Cash Flows:** Healthcare services model with repeat customers
- **Asset-Light Model:** Service-based revenue with minimal capital intensity
- **Recession-Resistant:** Wellness and aesthetic treatments show category resilience
- **Management Discipline:** Controlled cost structure and margin expansion

**‚úÖ GROWTH CATALYSTS:**

- **Service Mix Evolution:** Growing segments (65.5%) driving margin expansion
- **Operational Efficiency:** Marketing optimization created $484K EBITDA uplift
- **Cross-Selling Opportunities:** Multiple service lines per customer relationship

---

### üìà **NORMALIZED EBITDA BRIDGE ANALYSIS**

**Path to Sustainable Earnings Power:**

- **Reported 2024 EBITDA:** $1.57M (42.1% margin)
- **Marketing Normalization:** -$484K (unsustainable low spend)
- **Normalized EBITDA:** $1.08M (29.1% margin)
- **Industry Benchmark Range:** 25-35% EBITDA margins
- **Assessment:** Conservative normalization within industry standards

---

## SLIDE 2: VALUATION & RECOMMENDATION

### üéØ **ENTERPRISE VALUATION SUMMARY**

**EPV Methodology (Greenwald Framework):**

- **Normalized Owner Earnings:** $1.08M (2024 baseline)
- **Service Line Weighted Growth:** Mixed portfolio approach
- **Terminal Value Assumption:** Conservative healthcare services multiple
- **Target Capital Structure:** 40% debt capacity

| **Valuation Method**   | **Enterprise Value** | **Multiple** |
| ---------------------- | -------------------- | ------------ |
| **EPV (Primary)**      | $5.97M               | 5.5x EBITDA  |
| **Revenue Multiple**   | $5.97M               | 1.6x Revenue |
| **Industry Benchmark** | $5.4M - $6.6M        | 5.0x - 6.0x  |

**Equity Value:** $3.82M (after $2.15M net debt adjustment)

---

### ‚ö†Ô∏è **INVESTMENT RISKS & MITIGANTS**

| **Risk Factor**                    | **Impact** | **Mitigation Strategy**                           |
| ---------------------------------- | ---------- | ------------------------------------------------- |
| **Marketing Spend Sustainability** | **HIGH**   | Implement gradual marketing ramp-up plan          |
| **Injectable Revenue Decline**     | **MEDIUM** | Diversify into growing wellness/surgery segments  |
| **Customer Concentration**         | **MEDIUM** | Expand service offerings and geographic reach     |
| **Economic Sensitivity**           | **LOW**    | Healthcare services show recession resilience     |
| **Regulatory Changes**             | **LOW**    | Well-established industry with stable regulations |

---

### üèÜ **INVESTMENT RECOMMENDATION: FAVORABLE**

**Investment Rationale:**

- **Attractive Entry Multiple:** 5.5x EBITDA below industry median (6-8x)
- **Defensive Business Model:** Healthcare services with predictable cash flow
- **Portfolio Diversification:** Growing segments offset declining categories
- **Operational Upside:** Marketing optimization and cross-selling opportunities
- **Management Quality:** Demonstrated cost discipline and margin expansion

---

### üé≤ **SCENARIO ANALYSIS**

| **Scenario**      | **EBITDA** | **Multiple** | **Enterprise Value** | **IRR (5-year)** |
| ----------------- | ---------- | ------------ | -------------------- | ---------------- |
| **Base Case**     | $1.08M     | 5.5x         | $5.97M               | **18-22%**       |
| **Upside Case**   | $1.25M     | 6.0x         | $7.50M               | **24-28%**       |
| **Downside Case** | $950K      | 5.0x         | $4.75M               | **12-16%**       |

---

### ‚úÖ **KEY CONDITIONS FOR DEAL EXECUTION**

**Due Diligence Focus Areas:**

1. **Marketing Spend Validation:** Confirm sustainable marketing requirements
2. **Customer Concentration Analysis:** Assess top 20 customer dependency
3. **Service Line Profitability:** Validate segment-level margins and growth drivers
4. **Working Capital Requirements:** Confirm cash conversion cycle characteristics
5. **Management Team Assessment:** Evaluate operational and growth capabilities

**Deal Structure Recommendations:**

- **Purchase Price:** $3.8M equity value (target negotiation range)
- **Financing Structure:** 40% debt, 60% equity (conservative leverage)
- **Management Rollover:** 10-15% equity retention for alignment
- **Earnout Component:** 20% tied to growth targets and margin sustainability

**Investment Timeline:**

- **Hold Period:** 4-6 years (typical PE timeframe)
- **Value Creation Levers:** Operational improvements, service expansion, bolt-on acquisitions
- **Exit Strategy:** Strategic sale to healthcare consolidator or industry player

---

### üéØ **FINAL RECOMMENDATION**

**PROCEED WITH INVESTMENT COMMITTEE APPROVAL**

This medispa investment represents a compelling value opportunity in the defensive healthcare services sector. The combination of reasonable entry valuation, diversified revenue streams, and demonstrated operational leverage provides an attractive risk-adjusted return profile suitable for our fund's investment criteria.

**Expected IRR Range:** 18-22% (Base Case) | **Risk-Adjusted MOIC:** 2.2x - 2.8x

---

_Analysis prepared using Summit EPV Valuation System | Value Investing & Private Equity Framework_
_Financial data normalized to conservative industry standards | All figures in USD_
